CSI Market
Sign In | Register

Sorrento Therapeutics Inc (SRNEQ) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access SRNEQ Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Sorrento Therapeutics Inc generates earnings and manages operating expenses.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
Q2 2023 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Revenues
Revenue From Contract With Customer Including Assessed Tax15.03
Total Revenue15.03
Costs & Expenses
Cost of Goods and Services Sold6.56
Gross Profit8.46
Selling, Administration, Marketing48.94
Depreciation & Amortization1.13
Research and Development Expense (Excluding Acquired in Process Cost)33.27
Impairment of Intangible Assets (Excluding Goodwill)0.47
Other Operating Expense / -Income1.89
Legal Fees0.00
Total operating costs including COS92.26
Operating income / -loss-77.23
Interest Expense2.67
Interest Expense, Borrowings1.90
Net Interest Expense / -Income2.67
Extinguishment of Debt0.00
Loss / -Gain on Investment0.00
Foreign Currency Transaction Gain (Loss), before Tax-0.16
Other loss / -income6.12
Total costs & expenses122.89
Income & Taxes
Income / -loss before income taxes-107.87
Income taxes expenses / -benefit0.67
Income after income taxes-108.54
Net income / -loss of other equity0.00
Income / -loss from continuing operations-108.54
Non-controlling interests-13.32
Net income / -loss-108.54
Income / -loss to shareholder-95.21
EBIT-105.20
EBITD-101.60
EBITDA-101.60
Earnings Per Share
Basic EPS (excl. extra items)-0.17
Basic Net EPS-0.17
Basic shares outstanding (Mill. of Units)551.28
Diluted Net EPS-0.17
Diluted average shares (Mill. of Units)551.28
4 historic quarters locked

Sign in to unlock the full Sorrento Therapeutics Inc income statement history.

Sign In Create Free Account

About SRNEQ Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.